Innovations in synthetic chemistry help identify new cancer therapies
The pathway to discovering and developing cancer therapies is not always linear, but well-designed models incorporating smart chemical innovations can provide elegant solutions to treatments for some of the most difficult cancers. Some of these efforts were shared on June 22 during the American Association for Cancer Research 2020 virtual annual meeting II. Read More
ThermoGenesis launches new cell processing products
ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global distribution agreement. Read More
Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to build genomics startups. Read More
From DNA to precision medicine, researchers discuss breakthroughs in cancer research
From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer, researchers from around the globe shared their progress with the cancer research community on June 22 at the opening plenary session of the American Association for Cancer Research 2020 virtual annual meeting II. Read More
Therapeutic Solutions to use immunotherapy for COVID-19
Therapeutic Solutions plans to develop its clinical stage cancer immunotherapy treatment StemVacs for treatment of COVID-19 patients. Read More
New consortium formed to develop cell-based cancer vaccines
A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic cell cancer vaccines. Read More
Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron. Read More
Ideaya and GSK partner on synthetic lethality programs
Ideaya Biosciences and GlaxoSmithKline (GSK) have formed a strategic partnership in the emerging oncology field of synthetic lethality. Read More
Sexton, BioSpherix collaborate to support cell & gene therapy needs
Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish. Read More
Kite to manufacture CAR T-cell therapy in Europe
Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European facility. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter